Regulus Therapeutics

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

San Diego, US
96 (est)

Key People at Regulus Therapeutics

Kleanthis G. Xanthopoulos

Kleanthis G. Xanthopoulos

President & CEO
Peter S. Linsley

Peter S. Linsley

David Baltimore

David Baltimore


Regulus Therapeutics Locations

San Diego, US

Regulus Therapeutics Metrics

Regulus Therapeutics Summary

Founding Date


Market capitalization

$145 M

Closing share price


Regulus Therapeutics Market Value History

Regulus Therapeutics News

Regulus Therapeutics Company Life